Skip to content
This website includes promotional information and is intended for UK healthcare professionals only. This website has been developed and funded by Exeltis UK.

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to pharmacovigilance.uk@exeltis.com

About

Femoston® is designed around
women’s natural hormone
balance.

Femoston® is designed around women’s natural hormone balance

Femoston® contains a well-ballanced combination of oestradiol and progestogen. 1-4

Advantages of Oestradiol

Oestradiol is a body identical oestrogen, structurally identical to endogenous oestrogen. 1-4, 5

Advantages of Dydrogesterone

Dydrogesterone is associated with a lower breat cancer and VTE risk compared to other synthetic progestogens.8-10

Find out more

Cardiovascular safety: no higher risk vs other HRTs. 12, 13

Find out more

Dydrogesterone is highly comparable to the body’s natural progesterone. 6, 7

The Importance of Balanced Progestogen in HRT 14

01

Endometrial hyperplasia

Unopposed estrogen replacement is associated with a significant increase in the risk of endometrial hyperplasia that is both dose and duration dependent with exposure between one and three years.

02

Minimise the risk

Non-hysterectomised women require progestogen administered for 12-14 days in a sequential regimen and daily in a continuous combined regimen to minimise the risk of endometrial hyperplasia and endometrial cancer associated with unoposed estrogen exposure.

03

Long-term use

Long-term use of sequential combined HRT for >5 years may be associated with a small increase in risk of endometrial hyperplasia and endometrial cancer, with the risk being dose and duration dependent in relation to progestogen intake.

04

Endometrial Risk

Studies suggest that women taking sequential HRT with less than 10 days of progestogen each month are at increased risk of endometrial hyperplasia and endometrial cancer.

05

Safe HRT up to 5 years

However, progestogen intake in the recommended doses for 12-14 days a month does not appear to be associated with a significant increase in risk of endometrial hyperplasia for up to 5 years of use.

Femoston® is also approved for the prevention of osteoporosis* 1,2,4

Femoston®-conti 1mg/5mg, Femoston® 1/10mg and 2/10mg film-coated tablets are also indicated for the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. 1,2,4

 

Menopause increases the risk of osteoporosis

Up to 20% of bone can be lost during this period. 15

1 in 2 postmenopausal women develop osteoporosis

Most will suffer a fracture during their lifetime. 15

The earlier in life menopause occurs, the higher the fracture rate. 16

*Femoston® conti 0.5/2.5mg is not approved for the prevention of osteoporosis.

Read more

Femoston® 1/10mg and 2/10mg are both effective in preserving bone density at the key regions of lumbar spine and femoral neck of hip.17

Abbreviations: HRT, hormone replacement therapy; SE, standard error; VTE, venous thromboembolism

References: 1. Femoston® 1mg/10mg Summary of Product Characteristics. 2. Femoston® 2/10mg Summary of Product Characteristics. 3. Femoston®-conti 0.5mg/2.5mg Summary of Product Characteristics. 4. Femoston®-conti 1mg/5mg Summary of Product Characteristics. 5. Pattimakiel L and Thacker HL. Cleveland Journal of Medicine. 2011:78;12. Available from: https://www.ccjm.org/content/ccjom/78/12/829.full.pdf [accessed November 2025]. 6. Dydrogesterone. PubChem. National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone [Accessed November 2025]. 7. Progesterone. PubChem. National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Progesterone [Accessed November 2025]. 8. Glynne S et al. Menopause. 2025;32:103–1117. 9. Menopause: identification and management. NICE guideline NG23,November 2024. Available from https://www.nice.org.uk/guidance/ng23 [Accessed November 2025]. 10. Panay, N. et al. Climacteric. 2024;27(5):441–457. 11. Menopause: identification and management: from NICE guideline to practice. British Menopause Society. Available from Menopause: identification and management [Accessed November 2025]. 12. Pickar JH et al. Climacteric. 2020;23:550–558. 13. Stanczyk FZ et al. J Clin Endrocrinol Metab. 2014; 99(1):56-58. 14. BMS.2022. Progestogens and endometrial protection. Available at: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf [Accessed November 2025]. 15. Menopause & bone loss. Endocrine.org. Available from: https://www.endocrine.org/patient-engagement/endocrine-library/menopause-and-bone-loss [Accessed November 2025]. 16. Gallagher JC. Menopause. 2007;14(3 Pt 2):567–571. 17. Lees B & Stevenson JC. Osteoporosis Int. 2001;12:251–258

You are now leaving exeltishub.co.uk and going to an external site.

Exeltis is not responsible for websites it links to. Where our site contains links to other sites and resources provided by third parties, these links are provided for your information only.

EXE-E/IPR-CORP-2018-v6 | March 2026
Cancel

This is a promotional website developed and funded by Exeltis UK and it is intended for UK healthcare professionals only.

Please confirm whether you are a UK registered healthcare professional by selecting one of the options below:
EXE-E/IPR-CORP-2388-v1 | Oct 2025